体外血液净化与心脏手术后急性肾损伤:SIRAKI02随机临床试验
SIRAKI02为西班牙2家三级医院开展的双盲随机临床试验,纳入343例18岁以上、非急诊心脏手术且CSA-AKI高危患者,1:1随机接受体外循环中连接非选择性体外血液净化装置或标准治疗。主要终点为随机化后7天内CSA-AKI发生率,EBP组28.4%(95%CI 21.7%-35.8%)vs 标准治疗组39.7%(95%CI 32.3%-47.3%),P=.03;采用对数二项模型校正差值10.4%(95%CI 2.3%-18.5%),P=.01。多数预设临床次要终点及事后探索性终点无显著差异(P>.05)。敏感性分析提示合并慢性肾脏病、糖尿病、高血压、左心室射血分数低(<40%)及体重指数较低(<30)的患者中EBP降低CSA-AKI更有效。两组不良事件追踪无差异。
要点
- 非急诊心脏手术CSA-AKI高危患者,体外循环中连接非选择性EBP装置,术后7天CSA-AKI发生率28.4% vs 标准治疗39.7%(P=.03),校正差值10.4%(95%CI 2.3%-18.5%,P=.01)。
- 多数预设临床次要终点及事后探索性终点两组无显著差异(P>.05)。
- 敏感性分析显示,合并慢性肾脏病、糖尿病、高血压、左心室射血分数<40%、体重指数<30的患者中EBP降低CSA-AKI更有效。
- 两组不良事件追踪无差异。
- 研究纳入18岁以上、非急诊心脏手术且CSA-AKI高危患者,双盲设计,西班牙2家三级医院。
适用人群与场景
- 18岁及以上、接受非急诊心脏手术且为CSA-AKI高危的患者,2016年6月15日至2021年11月5日入组,随访至2022年2月5日。
处置流程与药物剂量
- 干预组在体外循环回路中连接非选择性EBP装置(丙烯腈-甲基烯丙基磺酸钠/聚乙烯亚胺膜)。
- 对照组接受标准治疗。
研究设计与关键结果
- 双盲随机临床试验,西班牙2家三级医院,筛查1156例,随机343例(EBP组169例,标准治疗组174例),平均(SD)年龄69(9)岁,女性119例。
- 主要终点随机化后7天CSA-AKI发生率:EBP组28.4%(95%CI 21.7%-35.8%)vs 标准治疗组39.7%(95%CI 32.3%-47.3%),P=.03;对数二项模型校正差值10.4%(95%CI 2.3%-18.5%),P=.01。
- 多数预设临床次要终点及事后探索性终点无显著差异(P>.05)。
- 敏感性分析中,合并慢性肾脏病、糖尿病、高血压、左心室射血分数<40%、体重指数<30的患者,EBP在降低CSA-AKI方面更有效。
- 两组不良事件追踪无差异。
证据类型、等级与局限
- 证据类型:双盲随机临床试验(SIRAKI02,ClinicalTrials.gov NCT02518087)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在非急诊心脏手术人群中,于体外循环回路连接非选择性EBP装置与术后7天CSA-AKI显著降低相关。
- 敏感性分析提示合并慢性肾脏病、糖尿病、高血压、左心室射血分数<40%、体重指数<30的患者可能获益更多。
- 多数预设临床次要终点及事后探索性终点无显著差异(P>.05),两组不良事件追踪无差异。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Cardiac surgery-associated acute kidney injury (CSA-AKI) remains a significant problem following cardiopulmonary bypass (CPB). Various strategies are proposed to attenuate CSA-AKI, including extracorporeal blood purification (EBP), but little is known about the effect of EBP through an acrylonitrile-sodium methallylsulfonate/polyethyleneimine membrane during CPB.
OBJECTIVE: To determine whether the use of an EBP device in a nonemergent cardiac surgery population reduces CSA-AKI after CPB.
DESIGN, SETTING, AND PARTICIPANTS: This double-blind, randomized clinical trial was conducted in 2 tertiary hospitals in Spain. Patients 18 years or older undergoing nonemergent cardiac surgery who were at high risk for CSA-AKI were enrolled from June 15, 2016, through November 5, 2021, with follow-up data through February 5, 2022. Of 1156 patients assessed, 343 patients were randomized (1:1) to either receive EBP or standard care.
INTERVENTION: Nonselective EBP device connected to the CPB circuit.
MAIN OUTCOMES AND MEASURES: The primary outcome was the rate of CSA-AKI in the 7 days after randomization.
RESULTS: Among 343 patients randomized (169 to receive EBP and 174 to receive usual care), the mean (SD) age was 69 (9) years and 119 were females. The rate of CSA-AKI was 28.4% (95% CI, 21.7%-35.8%) in the EBP group vs 39.7% (95% CI, 32.3%-47.3%) in the standard care group (P = .03), with an adjusted difference of 10.4% (95% CI, 2.3%-18.5%) using a log-binomial model (P = .01). No significant differences (P > .05) were observed in most of the predefined clinical secondary end points or post hoc exploratory end points. In a sensitivity analysis, EBP was found to be more effective in terms of CSA-AKI reduction in patients with chronic kidney disease, diabetes, hypertension, low left ventricular ejection fraction (<40%), and lower body mass index (<30). No differences were observed between the groups in adverse events tracking.
CONCLUSIONS AND RELEVANCE: The use of a nonselective EBP device connected to the CPB circuit in a nonemergent population of patients undergoing cardiac surgery was associated with a significant reduction of CSA-AKI in the first 7 days after surgery.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02518087.
参考来源
- Pérez-Fernández X, Ulsamer A, Cámara-Rosell M, et al. Extracorporeal Blood Purification and Acute Kidney Injury in Cardiac Surgery: The SIRAKI02 Randomized Clinical Trial. JAMA. 2024. PMID: 39382234. doi:10.1001/jama.2024.20630
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。